There were some posts recently re the possible role of the glutaminase switch in leading to castration resistance. The following trial - A Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With the PARP Inhibitor Talazoparib in Participants With Metastatic Castration-Resistant Prostate Cancer is opening in July to test this option
Although it includes a PARP inhibitor, this trial is looking at only men who test negative for BRCA.